Concentric Analgesics' new drug ca-008 for postoperative pain is recognized by FDA for breakthrough therapies
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Today, Co
ncentric Bio
medicine(Inc.)(announced that it is thenew drug(recognized by the U.SFDA( a breakthrough therapythe CA-008 developed by the CA-
ncentric Analgesics is a non-opioiddrugof "first-in-class" (it can be quickly converted into a powerful TRPV1 agonist, capsaicin)After a single local injection, CA-008 can provide lasting pain relief by selectively desensitizing the pain's conduction nerve fibers, and does not produce numbness or weaknessinjections of CA-008 during surgery are expected to help patients eliminate the need for opioids during postoperative recoveryIt's worth noting that the drug was approved by the FDA in Decemberthe CA-008 was identified as a breakthrough therapy and was in a 1b placebo-controlled clinical trial (supported by data, in patients receiving a cystic excision nectomy) in this study, the highest dose of CA-008 reduced pain intensity by 63% compared to placebo, resulting in a statistically significant and clinically significant reduction in pain intensity CA-008 also showed statistically significant pain reduction at 48h, 72h, 96h, and 120h points in time important, opioid consumption in patients using CA-008 was reduced by nearly 50 percent compared to placebos In addition, studies have shown that CA-008 is safe and well tolerated at all doses
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
